AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01222156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetecs Catheter Guidance Control and Imaging system
Description: Magnetecs Catheter Guidance Control and Imaging (CGCI) system
Study NCT00450008 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GM-CSF
Description: fixed dose of 250 mcg/m2, 3 days per week by subcutaneous injection
Study NCT00450008 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: thalidomide
Description: Thalidomide by oral administration at a fixed dose of 200 mg. Prophylactic Coumadin® by oral administration at a fixed dose of 2.5 mg to prevent thromboembolic events (DVT and TIA/stroke) during Thalidomide administration. Thalidomide and Coumadin will be given daily at bedtime without interruption.
Study NCT00450008 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel
Description: Docetaxel will be administered by intravenous piggyback over 1 hour at 75mg/m² every 3 weeks. Pre-medication for the docetaxel infusion will consist of dexamethasone 8 mg administered orally 12 hours, 3 hours and 1 hour before docetaxel.
Study NCT03229343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive care
Description: supportive care, systematic and joint to pneumological consultation, monthly, starting at M0 and continuing up to M6.
Study NCT03700684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lee Silverman Voice Treatment
Description: Persons with Parkinson's disease receive sixteen hours of voice treatment over a four week period. Participants will practice the vocal exercises at home for an additional four weeks.
Study NCT03700684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeechVive
Description: Persons with Parkinson's disease wear the SpeechVive device several hours a day over an eight week period during opportunities for communication.
Study NCT03700684 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Persons assigned to the non-treatment control group will not participate in voice treatment.
Study NCT00318942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloids
Description: Isotonic or hypertonic saline or Ringer Lactate or any other crystalloids, at the necessary dose to restore hemodynamic for all ICU stay
Study NCT00318942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloids
Description: Gelatines, Albumine, Starch, or any other colloids, at the necessary dose to restore hemodynamic (starch cumulative daily dose should not exceed 35/40 ml/kg), for all ICU stay
Study NCT00318942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloids
Description: Any crystalloids given for correction of hypovolemia during all ICU stay
Study NCT00318942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloids
Description: Any colloids given for correction of hypovolemia during all ICU stay
Study NCT01676831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical resiquimod 0.03%
Description: topical resiquimod 0.03% applied initially 5 times weekly for 8 weeks with adjustments up or down based upon tolerability followed by 4 weeks rest followed by another 8 weeks of treatment followed by another 4 week rest period.
Study NCT01406418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CR6261 5 mg/kg
Description: Administered as a single 2-hour intravenous infusion
Study NCT00948584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin dose titration system using a SMS
Description: We applied 'Insulin dose titration system in diabetic patients using a short messaging service automatically produced by a knowledge matrix' for 12 weeks in the intervention group. In the control group, a conventional insulin titration schedule was used. The insulin used in this study was Lantus (insulin glargine).
Study NCT00594425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate (MAL) PDT
Description: Cream application followed by illumination with red light
Study NCT00594425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methyl aminolevulinate (MAL) PDT
Description: Cream application followed by illumination with red light
Study NCT00546598 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Total hip replacement/arthroplasty
Description: Hip replacement
Study NCT02558829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macimorelin
Description: macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose
Study NCT02558829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin, 0.10 U/kg (0.15 U/kg if BMI > 30 kg/m2), intravenous injection, single dose
Study NCT00745589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevelamer hydrochloride
Description: First-line higher dose (that is, 800mg TDS and up to a maximum of 1200mg TDS) sevelamer hydrochloride will be compared against low dose second-line sevelamer hydrochloride (that is, fixed dose of 400mg TDS)
Study NCT03573011 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]PSMA-11
Description: 18F-PET imaging
Study NCT04180384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol
Description: Paclitaxel:~5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13- ester with (2R,3S)-N-benzoyl-3-phenylisoserine~HM30181 methanesulfonate monohydrate:~N-(2-(2-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide Methanesulfonate monohydrate
Study NCT04180384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oraxol
Description: Paclitaxel:~5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13- ester with (2R,3S)-N-benzoyl-3-phenylisoserine~HM30181 methanesulfonate monohydrate:~N-(2-(2-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide Methanesulfonate monohydrate
Study NCT01642875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Description: Standard enteral diet is administered through a nasojejunal tube. Enteral nutrition is started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated level.
Study NCT01642875 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral nutrition
Description: Oral diet is started from the 2nd postoperative day and oral intake is advanced as tolerated
Study NCT00538785 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Motavizumab
Description: 15 mg/kg IM administered at monthly intervals
Study NCT00538785 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Palivizumab
Description: 15 mg/kg IM administered at monthly intervals
Study NCT04661761 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Paraffin Pellets from Aurosan GmbH
Description: 1 to 2 minutes pre-chewing time chewing Paraffin Pellets from Aurosan GmbH, after which the amount of saliva is collected over a period of five minutes. The patient may chew the chewing gum once per second; after each minute the produced amount of saliva is spit in a cup, the whole amount measured after 5 minutes.
Study NCT04661761 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Chewing wax from the Saliva-Check Buffer from GC Europe
Description: 1 to 2 minutes pre-chewing time chewing wax from the Saliva-Check Buffer from GC Europe, after which the amount of saliva is collected over a period of five minutes. The patient may chew the chewing gum once per second; after each minute the produced amount of saliva is spit in a cup, the whole amount measured after 5 minutes.
Study NCT04673110 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil to Lymphocyte Ratio and C-reactive protein
Description: Zahorec et al. identified the neutrophil-lymphocyte ratio (NLR) as an inflammation marker in critical patients, defining as the absolute neutrophil count divided by the absolute lymphocyte count
Study NCT05290376 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical placement of long dental implants
Description: Two interforaminal implants were placed in the canine region
Study NCT05290376 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: overdenture supported by RTX attachment system
Description: Control group: Implants were loaded after three months by RTX supported overdenture study group: Implants were loaded after four weeks by RTX supported overdenture
Study NCT03581890 — intervention group
Intervention type: OTHER
Intervention: Socioeconomic position
Description: Socioeconomic position is the exposure in both study 1 and 2. Four different socioeconomic measures will be tested. The primary socioeconomic position measure is highest attained education the year before surgery (short/medium/long). Secondary measures are:~1. age- and sex-adjusted available income the year before surgery~2. Cohabitation status at the year of surgery (living alone/living with a partner) at the year of surgery.~3. Urbanicity (in four officially, predefined categories).
Study NCT04144127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Soccer
Description: * Soccer drills and other fitness routines (two 1-hour sessions per week)~* In person education in Life's Simple 7 to help improve life through Lifestyle changes: smoking status, physical activity, weight, diet, blood glucose, cholesterol, and blood pressure.
Study NCT00196183 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trigger-guided catheter-ablation
Description: trigger-guided ablation of paroxysmal atrial fibrillation
Study NCT00196183 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trigger+substrate-guided catheter ablation
Description: trigger-+substrate guided ablation of paroxysmal atrial fibrillation
Study NCT00631761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational workshop
Description: The intervention group will view a 20 minute video, receive a 30 minute didactic lecture on urethrocystoscopy, and 30 minute coaching/practice performing diagnostic cystoscopy on anatomic replicas.
Study NCT00631761 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no intervention (usual resident activities)
Description: usual activities
Study NCT00862420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel (SR25990)
Description: oral administration (tablets)
Study NCT00862420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticlopidine
Description: oral administration (tablets)
Study NCT02799420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GastroFlex UHD, Cellvizio; Mauna Kea Technologies, Paris, France
Description: The patients who enrolled the pCLE group will undergo endoscopic biopsy using pCLE. The cancerous lesion is observed using probe-based confocal laser endomicroscopy. The biopsy was done at the most suspicious parts of the cancerous lesion.
Study NCT02799420 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: white light endoscopy (WLE)
Description: The patients who enrolled this group will undergo endoscopic biopsy under standard white light endoscopy
Study NCT03277820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probactiol Mini
Description: 6 droplets of Probactiol Mini contain 1 billion bacteria (Lactobacillus rhamnosus GG and Bifidobacterium lactis BB-12)
Study NCT02426489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI + PEM image
Description: Effect of positron emission mammography on diagnostic accuracy
Study NCT01733212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginger
Description: Ginger is an herb. The rhizome (underground stem) is used as a spice and also as a medicine. It can be used fresh, dried and powdered, or as a juice or oil. Two capsules (1g each) of dry powdered ginger are given, one capsule a half-hour before induction of anesthesia and the second 2h after surgery.
Study NCT01733212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Two capsules (1g each) of placebo, one capsule a half-hour before induction of anesthesia and the second 2h after surgery.
Study NCT04319497 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Subjective refraction
Description: Subjective refraction measurements will be performed by two testers for all the patients included
Study NCT04319497 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Autorefraction
Description: Five autorefraction measurements will be performed for all the patients included
Study NCT04319497 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Wavefront aberrometry
Description: Five wavefront measurements will be performed for all the patients included
Study NCT02820532 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Protura Treatment table
Description: The treatment couch will be moved according to the respiratory motion of the patient. As a reference first the respiration will be measured without couch motion, than the couch will be switched on and we will evaluate if the respiration changes due to the motion of the couch. This procedure will be repeated once.
Study NCT02486341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Continuous glucose monitoring system over 120-hour period.
Study NCT04613843 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water Stirring
Description: Following an active heating protocol, the cooling intervention includes vigorous water stirring throughout cold water immersion.
Study NCT04613843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Water Stirring
Description: Following an active heating protocol, the cooling intervention includes no water stirring throughout cold water immersion.
Study NCT03253562 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin Pill
Description: a biguanide used as an insulin sensitizer for patients suffering from type 2 diabetes mellitus
Study NCT03253562 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vildagliptin 50 mg
Description: Dpp4i antihyperglycemic drug used for treatment of type 2 diabetes mellitus
Study NCT04532580 — intervention group
Intervention type: DEVICE
Intervention: Diagnosis of fracture on X-Ray Radiographs
Description: Diagnosis of fracture on X-Ray Radiographs with and without the assistance of Boneview Software
Study NCT03874429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T2259
Description: Sodium Hyaluronate and Trehalose
Study NCT03874429 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vismed multi
Description: HA
Study NCT05273073 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Each sachet consists of 30 billion colony-forming units (CFU) of six viable probiotic strains (Lactobacillus acidophilus BCMC® 12130 (107 mg), Lactobacillus casei subsp. BCMC® 12313 (107 mg), Lactobacillus lactis BCMC® 12451 (107 mg), Bifidobacterium bifidum BCMC® 02290 (107 mg), Bifidobacterium infantis BCMC® 02129 (107 mg), and Bifidobacterium longum BCMC® 02120 (107 mg).
Study NCT05273073 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo samples were identical to the probiotics in term of taste and texture without live microbial cells.
Study NCT01406418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CR6261 15 mg/kg
Description: Administered as a single 2-hour intravenous infusion
Study NCT02457234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cultural immersion
Description: The primary intervention was the cultural immersion within CIC. Unique to the Traditions study were culturally-adapted nutrition lessons incorporated into CIC and UDC. CIC had a high cultural dose as the Traditions lessons were implemented within the cultural immersion context of the camp. The UDC had moderate cultural dose from the Traditions lessons only. RSC was without cultural immersion and Traditions lessons or had zero cultural dose.
Study NCT02160002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Weaning from an incubator at a lower weight (1600 grams)
Description: Infants will be weaned from an incubator at a lower weight (1600 grams)
Study NCT02160002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Weaning from an incubator at a higher weight (1800 grams)
Description: Infants will be weaned from an incubator at a higher weight (1800 grams)
Study NCT00072527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IV
Study NCT00072527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: IV
Study NCT00072527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: IV
Study NCT00072527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: IV
Study NCT00072527 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02937584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP MDI (PT001) 14.4 μg
Description: Glycopyrronium
Study NCT01406418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CR6261 30 mg/kg
Description: Administered as a single 2-hour intravenous infusion
Study NCT01406418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CR6261 50 mg/kg
Description: Administered as a single 2-hour intravenous infusion
Study NCT01406418 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as a single 2-hour intravenous infusion
Study NCT00641420 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractionated Laser Resurfacing
Study NCT02937584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF MDI (PT005) 9.6 μg
Description: Formoterol Fumarate
Study NCT04107675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Cyclosporine A
Description: Liposomal Cyclosporine A is administered at different dosages in the first two arms (10 mg bid and 5 mg bid, respectively) with a new technology of nebulizing liquid drugs, creating an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
Study NCT04107675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liposomal Placebo
Description: Liposomal Placebo is administered with the same new technology of nebulizing liquid drugs used for L-CsA, creating an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
Study NCT03959683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trilogy Lithotrite
Description: The Trilogy has been FDA cleared for fragmentation of urinary tract calculi in the kidney, ureter, and bladder. Trilogy is a combined piezoelectric/pneumatic device capable of fragmenting calculi and aspirating stone debris. The novel technology in Trilogy has been demonstrated in bench testing to more quickly disintegrate stones compared to other devices.
Study NCT03959683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The ShockPulse-SE Lithotripsy System
Description: The ShockPulse-SE System is an electromechanical device capable of fragmenting calculi and aspirating stone debris. The novel technology in the ShockPulse-SE Lithotripsy System uses a single transducer and proprietary ShockPulse technology to generate both low-frequency mechanical impacts and high-frequency ultrasonic energy which quickly disintegrates stones.
Study NCT04132011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended Release Opioid Formulation, Shortened Intervals
Description: Extended release opioid, individualized total daily dose, dosing interval is less than every 12 hours
Study NCT04132011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended Release Opioid Formulation, Standard intervals
Description: Extended release opioid, individualized total daily dose, dosing interval is every 12 hours
Study NCT04132011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral tablet
Description: Lactose pill manufactured to mimic extended release opioid formulation
Study NCT02819232 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Detection of bacteria will be performed on a blood sample
Study NCT03673397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise, bicycle ergometer
Description: Exercise performed below individual anaerobic threshold for 30 minutes
Study NCT02685059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736 (Anti PD-L1)
Description: MEDI4736 1.5g total i.v. every 4 weeks~As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:~MEDI4736 in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by~MEDI4736 in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3).
Study NCT00815763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ginsenoside-Rd
Description: infusion ginsenoside-Rd 20 mg once a day and continued for 14 day
Study NCT00815763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: infusion placebo once a day and continued for 14 day